1Hay LC,Wilmshurst EG,Fulcher C.Unrecognized hypo-andhyperglycemia in well controlled patients with type 2 diabe smellitus:theresults of continuous glucose monitoring.Diabetes Teehnol Ther,2003,5(1):19-26.
2Rosenstock J,Dailey G,Massi-Benedetti M,et al.Reduced hypoglycemia risk with insulin glargine:a meta-analysis comparing insulin glargine withhuman NPH insulin in type 2 diabetes.Diabetes Care,2005;28(4):950-5.
5Reinhart L,Panning CA.Insulin glargine:a new long -ring insulin product.Am J Health Syst Pharm,2002,59(7):643-64.
6Heinemann 1,Linkeschova R,Rave K,et al.Time-actionprofile of the longacting insulin an slog insulin glargine(HOE901) in camparison with those of NPH insulin andplacebo.Diabetes Care,2000,23(5):644,9.
7Wang F,Carabino JM,Vergara CM.Insulin glargine:asys-tematic review of along acting insulin analogue.Clin Ther,2003,25(6):1541-1577.
4Dunn CJ, Plosker GL, Keating GM,et al. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs, 2003,63 : 1743-1778.
5Schaepelynck-Belicar P, Vague P, Simonin G, et al. Improved metabolic control in diabetic adolescents using the continuous glucose monitoring system (CGMS) . Diabetes Metab, 2003,29:608-612.
6Dailey G. New strategies for basal insulin treatment in type 2 diabetes mellitus. Clin Ther, 2004,26:889-901.
7Riddle MC, Rosenstock J, Gerich J. The treat-to-target thai:randomized addition of glarglne or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care, 2003,26:3080-3086.
8Muggeo M, Zoppini G, Bonora E, et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care, 2000,23:45-50.
9Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial:randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care, 2003,26:3080-3086.
10Klonoff DC. Continuous glucose monitoring: roadmap for 21 st century diabetes therapy. Diabetes Care, 2005,28 : 1231-1239.
3Wright A, Burden A C,Paisey R B, et aL Sulfonylurea inadequacy : effi-cacy of addition of insulin over 6 years in patients with type 2 diabetesin the UK Prospective Diabetes Study ( UKPDS 57 )[ J]. DiabetesCare ,2002,25:330-336.
